ID   LOX12_HUMAN             Reviewed;         663 AA.
AC   P18054; O95569; Q6ISF8; Q9UQM4;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 4.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Arachidonate 12-lipoxygenase, 12S-type;
DE            Short=12S-LOX;
DE            Short=12S-lipoxygenase;
DE            EC=1.13.11.31;
DE   AltName: Full=Lipoxin synthase 12-LO;
DE            EC=3.3.2.-;
DE   AltName: Full=Platelet-type lipoxygenase 12;
GN   Name=ALOX12; Synonyms=12LO, LOG12;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-322.
RX   PubMed=2244907; DOI=10.1016/0006-291X(90)91580-L;
RA   Yoshimoto T., Yamamoto Y., Arakawa T., Suzuki H., Yamamoto S.,
RA   Yokoyama C., Tanabe T., Toh H.;
RT   "Molecular cloning and expression of human arachidonate 12-
RT   lipoxygenase.";
RL   Biochem. Biophys. Res. Commun. 172:1230-1235(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-322.
RX   PubMed=2377602; DOI=10.1073/pnas.87.15.5638;
RA   Funk C.D., Furci L., Fitzgerald G.A.;
RT   "Molecular cloning, primary structure, and expression of the human
RT   platelet/erythroleukemia cell 12-lipoxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5638-5642(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ARG-261.
RX   PubMed=2217179; DOI=10.1073/pnas.87.19.7477;
RA   Izumi T., Hoshiko S., Raadmark O., Samuelsson B.;
RT   "Cloning of the cDNA for human 12-lipoxygenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7477-7481(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-261; SER-322 AND
RP   HIS-430.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ARG-261.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-112.
RX   PubMed=1447217;
RA   Yoshimoto T., Arakawa T., Hada T., Yamamoto S., Takahashi E.;
RT   "Structure and chromosomal localization of human arachidonate 12-
RT   lipoxygenase gene.";
RL   J. Biol. Chem. 267:24805-24809(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45.
RX   PubMed=1570320; DOI=10.1073/pnas.89.9.3962;
RA   Funk C.D., Funk L.B., Fitzgerald G.A., Samuelsson B.;
RT   "Characterization of human 12-lipoxygenase genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3962-3966(1992).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 340-427.
RC   TISSUE=Skin;
RX   PubMed=8304420;
RA   Hussain H., Shornick L.P., Shannon V.R., Wilson J.D., Funk C.D.,
RA   Pentland A.P., Holtzman M.J.;
RT   "Epidermis contains platelet-type 12-lipoxygenase that is
RT   overexpressed in germinal layer keratinocytes in psoriasis.";
RL   Am. J. Physiol. 266:C243-C253(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 531-663.
RA   Persson A.E., Lundeberg J., Uhlen M.;
RT   "EU-IMAGE: full-insert length sequencing of human cDNA clones.";
RL   Submitted (APR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   CATALYTIC ACTIVITY, KINETIC PARAMETERS, PATHWAY, AND SUBSTRATE
RP   SPECIFICITY.
RX   PubMed=1851637; DOI=10.1016/0005-2760(91)90128-5;
RA   Hada T., Ueda N., Takahashi Y., Yamamoto S.;
RT   "Catalytic properties of human platelet 12-lipoxygenase as compared
RT   with the enzymes of other origins.";
RL   Biochim. Biophys. Acta 1083:89-93(1991).
RN   [12]
RP   FUNCTION IN LIPOXIN SYNTHESIS, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND REACTION MECHANISM.
RX   PubMed=8250832; DOI=10.1042/bj2960127;
RA   Romano M., Chen X.S., Takahashi Y., Yamamoto S., Funk C.D.,
RA   Serhan C.N.;
RT   "Lipoxin synthase activity of human platelet 12-lipoxygenase.";
RL   Biochem. J. 296:127-133(1993).
RN   [13]
RP   CATALYTIC ACTIVITY, KINETIC PARAMETERS, PH DEPENDENCE, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=8319693; DOI=10.1111/j.1432-1033.1993.tb17988.x;
RA   Chen X.S., Brash A.R., Funk C.D.;
RT   "Purification and characterization of recombinant histidine-tagged
RT   human platelet 12-lipoxygenase expressed in a baculovirus/insect cell
RT   system.";
RL   Eur. J. Biochem. 214:845-852(1993).
RN   [14]
RP   CATALYTIC ACTIVITY, AND MUTAGENESIS OF HIS-355; HIS-360; HIS-365;
RP   HIS-383; HIS-392; LYS-416; ALA-417; VAL-418 AND HIS-540.
RX   PubMed=8500694;
RA   Chen X.S., Funk C.D.;
RT   "Structure-function properties of human platelet 12-lipoxygenase:
RT   chimeric enzyme and in vitro mutagenesis studies.";
RL   FASEB J. 7:694-701(1993).
RN   [15]
RP   SUBCELLULAR LOCATION, ENZYME REGULATION, AND INDUCTION.
RX   PubMed=8912711; DOI=10.1006/excr.1996.0317;
RA   Hagmann W., Gao X., Timar J., Chen Y.Q., Strohmaier A.R.,
RA   Fahrenkopf C., Kagawa D., Lee M., Zacharek A., Honn K.V.;
RT   "12-Lipoxygenase in A431 cells: genetic identity, modulation of
RT   expression, and intracellular localization.";
RL   Exp. Cell Res. 228:197-205(1996).
RN   [16]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=9751607;
RA   Nie D., Hillman G.G., Geddes T., Tang K., Pierson C., Grignon D.J.,
RA   Honn K.V.;
RT   "Platelet-type 12-lipoxygenase in a human prostate carcinoma
RT   stimulates angiogenesis and tumor growth.";
RL   Cancer Res. 58:4047-4051(1998).
RN   [17]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=16638750; DOI=10.1074/jbc.M601887200;
RA   Nie D., Krishnamoorthy S., Jin R., Tang K., Chen Y., Qiao Y.,
RA   Zacharek A., Guo Y., Milanini J., Pages G., Honn K.V.;
RT   "Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in
RT   prostate cancer cells.";
RL   J. Biol. Chem. 281:18601-18609(2006).
RN   [18]
RP   INDUCTION BY UV.
RX   PubMed=18755188; DOI=10.1016/j.febslet.2008.08.017;
RA   Yoo H., Jeon B., Jeon M.S., Lee H., Kim T.Y.;
RT   "Reciprocal regulation of 12- and 15-lipoxygenases by UV-irradiation
RT   in human keratinocytes.";
RL   FEBS Lett. 582:3249-3253(2008).
RN   [19]
RP   FUNCTION IN CELL MIGRATION.
RX   PubMed=22237009; DOI=10.1016/j.yexcr.2011.12.017;
RA   Klampfl T., Bogner E., Bednar W., Mager L., Massudom D., Kalny I.,
RA   Heinzle C., Berger W., Staettner S., Karner J., Klimpfinger M.,
RA   Fuerstenberger G., Krieg P., Marian B.;
RT   "Up-regulation of 12(S)-lipoxygenase induces a migratory phenotype in
RT   colorectal cancer cells.";
RL   Exp. Cell Res. 318:768-778(2012).
RN   [20]
RP   FUNCTION IN APOPTOTIC PROCESS, AND TISSUE SPECIFICITY.
RX   PubMed=23578768; DOI=10.1016/j.yexcr.2013.04.001;
RA   Weisinger G., Grafi-Cohen M., Hirsh M., Knoll E., Sharon O., Many A.,
RA   Limor R., Stern N.;
RT   "12S-Lipoxygenase is necessary for human vascular smooth muscle cell
RT   survival.";
RL   Exp. Cell Res. 319:1586-1593(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 172-662 IN COMPLEX WITH IRON
RP   IONS.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the lipoxygenase domain of human arachidonate
RT   12-lipoxygenase, 12s-type.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [22]
RP   VARIANT ARG-261.
RX   PubMed=15308583; DOI=10.1093/carcin/bgh260;
RA   Goodman J.E., Bowman E.D., Chanock S.J., Alberg A.J., Harris C.C.;
RT   "Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX)
RT   polymorphisms and colon cancer risk.";
RL   Carcinogenesis 25:2467-2472(2004).
RN   [23]
RP   VARIANT ARG-261, AND INVOLVEMENT IN COLORECTAL CANCER.
RX   PubMed=17151091; DOI=10.1093/carcin/bgl242;
RA   Tan W., Wu J., Zhang X., Guo Y., Liu J., Sun T., Zhang B., Zhao D.,
RA   Yang M., Yu D., Lin D.;
RT   "Associations of functional polymorphisms in cyclooxygenase-2 and
RT   platelet 12-lipoxygenase with risk of occurrence and advanced disease
RT   status of colorectal cancer.";
RL   Carcinogenesis 28:1197-1201(2007).
RN   [24]
RP   VARIANT ARG-261, AND INVOLVEMENT IN ESOPHAGEAL CANCER.
RX   PubMed=17460548; DOI=10.1097/FPC.0b013e328010bda1;
RA   Guo Y., Zhang X., Tan W., Miao X., Sun T., Zhao D., Lin D.;
RT   "Platelet 12-lipoxygenase Arg261Gln polymorphism: functional
RT   characterization and association with risk of esophageal squamous cell
RT   carcinoma in combination with COX-2 polymorphisms.";
RL   Pharmacogenet. Genomics 17:197-205(2007).
CC   -!- FUNCTION: Non-heme iron-containing dioxygenase that catalyzes the
CC       stereo-specific peroxidation of free and esterified
CC       polyunsaturated fatty acids generating a spectrum of bioactive
CC       lipid mediators. Mainly converts arachidonic acid to (12S)-
CC       hydroperoxyeicosatetraenoic acid/(12S)-HPETE but can also
CC       metabolize linoleic acid. Has a dual activity since it also
CC       converts leukotriene A4/LTA4 into both the bioactive lipoxin
CC       A4/LXA4 and lipoxin B4/LXB4. Through the production of specific
CC       bioactive lipids like (12S)-HPETE it regulates different
CC       biological processes including platelet activation. It also
CC       probably positively regulates angiogenesis through regulation of
CC       the expression of the vascular endothelial growth factor. Plays a
CC       role in apoptotic process, promoting the survival of vascular
CC       smooth muscle cells for instance. May also play a role in the
CC       control of cell migration and proliferation.
CC       {ECO:0000269|PubMed:16638750, ECO:0000269|PubMed:22237009,
CC       ECO:0000269|PubMed:23578768, ECO:0000269|PubMed:8250832,
CC       ECO:0000269|PubMed:9751607}.
CC   -!- CATALYTIC ACTIVITY: Arachidonate + O(2) = (5Z,8Z,10E,14Z)-(12S)-
CC       12-hydroperoxyicosa-5,8,10,14-tetraenoate.
CC   -!- CATALYTIC ACTIVITY: (7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-
CC       7,9,11,14-tetraenoate + H(2)O = (5S,6R,15S)-trihydroxy-
CC       (7E,9E,11Z,13E)-eicosatetraenoate.
CC   -!- CATALYTIC ACTIVITY: (7E,9E,11Z,14Z)-(5S,6S)-5,6-epoxyicosa-
CC       7,9,11,14-tetraenoate + H(2)O = (5S,14R,15S)-trihydroxy-
CC       (6E,8Z,10E,12E)-eicosatetraenoate.
CC   -!- COFACTOR:
CC       Name=Fe cation; Xref=ChEBI:CHEBI:24875;
CC       Note=Binds 1 Fe cation per subunit.;
CC   -!- ENZYME REGULATION: Activated by EGF. {ECO:0000269|PubMed:8912711}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=8 uM for arachidonate (at pH 7.0 and 37 degrees Celsius)
CC         {ECO:0000269|PubMed:1851637};
CC         KM=10 uM for arachidonate (at pH 8.0 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:8319693};
CC         KM=6.2 uM for arachidonate (at pH 7.4)
CC         {ECO:0000269|PubMed:8250832};
CC         KM=9 uM for linoleate (at pH 8.0 and 25 degrees Celsius)
CC         {ECO:0000269|PubMed:8319693};
CC         KM=7.9 uM for leukotriene A4 (at pH 7.4)
CC         {ECO:0000269|PubMed:8250832};
CC         KM=3 uM for eicosa-5,8,11,14,17-pentaenoate (at pH 7.0 and 37
CC         degrees Celsius) {ECO:0000269|PubMed:1851637};
CC         KM=35 uM for eicosa-8,11,14-trienoate (at pH 7.0 and 37 degrees
CC         Celsius) {ECO:0000269|PubMed:1851637};
CC         KM=14.3 uM for 5,6-epoxy-8,11,14-eicosatrienoate (at pH 7.4)
CC         {ECO:0000269|PubMed:8250832};
CC         Vmax=3 umol/min/mg enzyme with arachidonate as substrate (at pH
CC         8.0 and 25 degrees Celsius) {ECO:0000269|PubMed:8319693};
CC         Vmax=1.057 umol/min/mg enzyme with arachidonate as substrate (at
CC         pH 7.4) {ECO:0000269|PubMed:8250832};
CC         Vmax=0.0375 umol/min/mg enzyme with linoleate as substrate (at
CC         pH 8.0 and 25 degrees Celsius) {ECO:0000269|PubMed:8319693};
CC         Vmax=0.025 umol/min/mg enzyme with leukotriene A4 as substrate
CC         (at pH 7.4) {ECO:0000269|PubMed:8250832};
CC         Vmax=0.985 umol/min/mg enzyme with 5,6-epoxy-8,11,14-
CC         eicosatrienoate as substrate (at pH 7.4)
CC         {ECO:0000269|PubMed:8250832};
CC       pH dependence:
CC         Optimum pH is 7.5-8.0 (for arachidonate 12-lipoxygenase
CC         activity). {ECO:0000269|PubMed:8250832,
CC         ECO:0000269|PubMed:8319693};
CC   -!- PATHWAY: Lipid metabolism; hydroperoxy eicosatetraenoic acid
CC       biosynthesis. {ECO:0000269|PubMed:1851637}.
CC   -!- INTERACTION:
CC       P13647:KRT5; NbExp=7; IntAct=EBI-1633210, EBI-702187;
CC       P02545:LMNA; NbExp=4; IntAct=EBI-1633210, EBI-351935;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Membrane. Note=Membrane
CC       association is stimulated by EGF.
CC   -!- TISSUE SPECIFICITY: Expressed in vascular smooth muscle cells.
CC       {ECO:0000269|PubMed:23578768}.
CC   -!- INDUCTION: Down-regulated upon starvation, by UV-irradiation and
CC       15-lipoxygenase metabolites. {ECO:0000269|PubMed:18755188,
CC       ECO:0000269|PubMed:8912711}.
CC   -!- DISEASE: Esophageal cancer (ESCR) [MIM:133239]: A malignancy of
CC       the esophagus. The most common types are esophageal squamous cell
CC       carcinoma and adenocarcinoma. Cancer of the esophagus remains a
CC       devastating disease because it is usually not detected until it
CC       has progressed to an advanced incurable stage.
CC       {ECO:0000269|PubMed:17460548}. Note=Disease susceptibility may be
CC       associated with variations affecting the gene represented in this
CC       entry. Gln at position 261 may confer interindividual
CC       susceptibility to esophageal cancer (PubMed:17460548).
CC       {ECO:0000269|PubMed:17460548}.
CC   -!- DISEASE: Colorectal cancer (CRC) [MIM:114500]: A complex disease
CC       characterized by malignant lesions arising from the inner wall of
CC       the large intestine (the colon) and the rectum. Genetic
CC       alterations are often associated with progression from
CC       premalignant lesion (adenoma) to invasive adenocarcinoma. Risk
CC       factors for cancer of the colon and rectum include colon polyps,
CC       long-standing ulcerative colitis, and genetic family history.
CC       {ECO:0000269|PubMed:17151091}. Note=Disease susceptibility may be
CC       associated with variations affecting the gene represented in this
CC       entry. Gln at position 261 may confer interindividual
CC       susceptibility to colorectal cancer (PubMed:17460548).
CC       {ECO:0000269|PubMed:17460548}.
CC   -!- SIMILARITY: Belongs to the lipoxygenase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/alox12/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ALOX12ID620ch17p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M62982; AAA51533.1; -; mRNA.
DR   EMBL; M35418; AAA60056.1; -; mRNA.
DR   EMBL; M58704; AAA59523.1; -; mRNA.
DR   EMBL; AY527817; AAS00094.1; -; Genomic_DNA.
DR   EMBL; AC040977; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC069557; AAH69557.1; -; mRNA.
DR   EMBL; D12638; BAA02162.1; -; Genomic_DNA.
DR   EMBL; M87004; AAA51587.1; -; Genomic_DNA.
DR   EMBL; S68587; AAD14020.1; -; mRNA.
DR   EMBL; AF143883; AAD32700.1; -; mRNA.
DR   CCDS; CCDS11084.1; -.
DR   PIR; A38283; A38283.
DR   RefSeq; NP_000688.2; NM_000697.2.
DR   UniGene; Hs.654431; -.
DR   PDB; 2ABU; Model; -; A=2-663.
DR   PDB; 3D3L; X-ray; 2.60 A; A/B=172-663.
DR   PDBsum; 2ABU; -.
DR   PDBsum; 3D3L; -.
DR   ProteinModelPortal; P18054; -.
DR   SMR; P18054; -.
DR   BioGrid; 106740; 8.
DR   IntAct; P18054; 4.
DR   MINT; MINT-1206406; -.
DR   STRING; 9606.ENSP00000251535; -.
DR   BindingDB; P18054; -.
DR   ChEMBL; CHEMBL3687; -.
DR   GuidetoPHARMACOLOGY; 1387; -.
DR   SwissLipids; SLP:000000670; -.
DR   iPTMnet; P18054; -.
DR   PhosphoSitePlus; P18054; -.
DR   BioMuta; ALOX12; -.
DR   DMDM; 125987838; -.
DR   PaxDb; P18054; -.
DR   PeptideAtlas; P18054; -.
DR   PRIDE; P18054; -.
DR   Ensembl; ENST00000251535; ENSP00000251535; ENSG00000108839.
DR   GeneID; 239; -.
DR   KEGG; hsa:239; -.
DR   UCSC; uc002gdx.4; human.
DR   CTD; 239; -.
DR   DisGeNET; 239; -.
DR   GeneCards; ALOX12; -.
DR   H-InvDB; HIX0039067; -.
DR   HGNC; HGNC:429; ALOX12.
DR   HPA; CAB019287; -.
DR   HPA; HPA010691; -.
DR   MIM; 114500; phenotype.
DR   MIM; 133239; phenotype.
DR   MIM; 152391; gene.
DR   neXtProt; NX_P18054; -.
DR   OpenTargets; ENSG00000108839; -.
DR   PharmGKB; PA45; -.
DR   eggNOG; ENOG410IF0U; Eukaryota.
DR   eggNOG; ENOG410YN4N; LUCA.
DR   GeneTree; ENSGT00550000074415; -.
DR   HOGENOM; HOG000234358; -.
DR   HOVERGEN; HBG005150; -.
DR   InParanoid; P18054; -.
DR   KO; K00458; -.
DR   OMA; MRFHEDK; -.
DR   OrthoDB; EOG091G04A4; -.
DR   PhylomeDB; P18054; -.
DR   TreeFam; TF105320; -.
DR   BioCyc; MetaCyc:HS03167-MONOMER; -.
DR   BRENDA; 1.13.11.31; 2681.
DR   Reactome; R-HSA-2142696; Synthesis of Hepoxilins (HX) and Trioxilins (TrX).
DR   Reactome; R-HSA-2142700; Synthesis of Lipoxins (LX).
DR   Reactome; R-HSA-2142712; Synthesis of 12-eicosatetraenoic acid derivatives.
DR   UniPathway; UPA00881; -.
DR   EvolutionaryTrace; P18054; -.
DR   GeneWiki; ALOX12; -.
DR   GenomeRNAi; 239; -.
DR   PRO; PR:P18054; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000108839; -.
DR   CleanEx; HS_ALOX12; -.
DR   ExpressionAtlas; P18054; baseline and differential.
DR   Genevisible; P18054; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IDA:UniProtKB.
DR   GO; GO:0004052; F:arachidonate 12-lipoxygenase activity; IDA:UniProtKB.
DR   GO; GO:0051120; F:hepoxilin A3 synthase activity; TAS:Reactome.
DR   GO; GO:0047977; F:hepoxilin-epoxide hydrolase activity; ISS:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0016165; F:linoleate 13S-lipoxygenase activity; IDA:UniProtKB.
DR   GO; GO:0016702; F:oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen; TAS:Reactome.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0071396; P:cellular response to lipid; IEA:Ensembl.
DR   GO; GO:0061436; P:establishment of skin barrier; ISS:UniProtKB.
DR   GO; GO:0019395; P:fatty acid oxidation; IMP:UniProtKB.
DR   GO; GO:0051122; P:hepoxilin biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0051121; P:hepoxilin metabolic process; TAS:Reactome.
DR   GO; GO:1901751; P:leukotriene A4 metabolic process; IDA:UniProtKB.
DR   GO; GO:0043651; P:linoleic acid metabolic process; IDA:UniProtKB.
DR   GO; GO:2001303; P:lipoxin A4 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:2001306; P:lipoxin B4 biosynthetic process; IDA:UniProtKB.
DR   GO; GO:2001300; P:lipoxin metabolic process; TAS:Reactome.
DR   GO; GO:0019372; P:lipoxygenase pathway; IDA:UniProtKB.
DR   GO; GO:0006928; P:movement of cell or subcellular component; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0090331; P:negative regulation of platelet aggregation; ISS:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; IEA:Ensembl.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0030307; P:positive regulation of cell growth; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IMP:UniProtKB.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0051901; P:positive regulation of mitochondrial depolarization; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0072593; P:reactive oxygen species metabolic process; NAS:UniProtKB.
DR   GO; GO:0042554; P:superoxide anion generation; NAS:UniProtKB.
DR   Gene3D; 2.60.60.20; -; 1.
DR   InterPro; IPR000907; LipOase.
DR   InterPro; IPR013819; LipOase_C.
DR   InterPro; IPR020834; LipOase_CS.
DR   InterPro; IPR020833; LipOase_Fe_BS.
DR   InterPro; IPR001885; LipOase_mml.
DR   InterPro; IPR001024; PLAT/LH2_dom.
DR   PANTHER; PTHR11771; PTHR11771; 1.
DR   Pfam; PF00305; Lipoxygenase; 1.
DR   Pfam; PF01477; PLAT; 1.
DR   PRINTS; PR00087; LIPOXYGENASE.
DR   PRINTS; PR00467; MAMLPOXGNASE.
DR   SMART; SM00308; LH2; 1.
DR   SUPFAM; SSF48484; SSF48484; 1.
DR   SUPFAM; SSF49723; SSF49723; 1.
DR   PROSITE; PS00711; LIPOXYGENASE_1; 1.
DR   PROSITE; PS00081; LIPOXYGENASE_2; 1.
DR   PROSITE; PS51393; LIPOXYGENASE_3; 1.
DR   PROSITE; PS50095; PLAT; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Dioxygenase;
KW   Fatty acid metabolism; Hydrolase; Iron; Lipid metabolism; Membrane;
KW   Metal-binding; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome.
FT   CHAIN         1    663       Arachidonate 12-lipoxygenase, 12S-type.
FT                                /FTId=PRO_0000220682.
FT   DOMAIN        2    114       PLAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00152}.
FT   DOMAIN      115    663       Lipoxygenase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       360    360       Iron; catalytic.
FT   METAL       365    365       Iron; catalytic.
FT   METAL       540    540       Iron; catalytic.
FT   METAL       544    544       Iron; catalytic. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00726}.
FT   METAL       663    663       Iron; via carboxylate; catalytic.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00726}.
FT   MOD_RES     246    246       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:F1LQ70}.
FT   VARIANT     259    259       E -> K (in dbSNP:rs4987104).
FT                                /FTId=VAR_030471.
FT   VARIANT     261    261       Q -> R (in dbSNP:rs1126667).
FT                                {ECO:0000269|PubMed:15308583,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17151091,
FT                                ECO:0000269|PubMed:17460548,
FT                                ECO:0000269|PubMed:2217179,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018743.
FT   VARIANT     298    298       A -> T.
FT                                /FTId=VAR_004279.
FT   VARIANT     322    322       N -> S (in dbSNP:rs434473).
FT                                {ECO:0000269|PubMed:2244907,
FT                                ECO:0000269|PubMed:2377602,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018744.
FT   VARIANT     430    430       R -> H (in dbSNP:rs11571342).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_018745.
FT   MUTAGEN     355    355       H->Q: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     360    360       H->Q,Y: Complete loss of catalytic
FT                                activity. {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     365    365       H->Q: Complete loss of catalytic
FT                                activity. {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     383    383       H->Q: Altered catalytic activity and
FT                                protein expression.
FT                                {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     392    392       H->Q: No effect on catalytic activity.
FT                                {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     416    416       K->Q: Reduced catalytic activity. No
FT                                effect on the stereoselectivity of the
FT                                oxygenation reaction.
FT                                {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     417    417       A->I: Reduced catalytic activity. Alters
FT                                the stereoselectivity of the oxygenation
FT                                reaction. {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     418    418       V->M: No effect on catalytic activity. No
FT                                effect on the stereoselectivity of the
FT                                oxygenation reaction.
FT                                {ECO:0000269|PubMed:8500694}.
FT   MUTAGEN     540    540       H->Q: Complete loss of catalytic
FT                                activity. {ECO:0000269|PubMed:8500694}.
FT   CONFLICT    189    192       RVYT -> PCLH (in Ref. 1; AAA51533).
FT                                {ECO:0000305}.
FT   CONFLICT    345    345       S -> C (in Ref. 1; AAA51533).
FT                                {ECO:0000305}.
FT   CONFLICT    389    389       L -> P (in Ref. 2; AAA60056).
FT                                {ECO:0000305}.
FT   HELIX       182    195       {ECO:0000244|PDB:3D3L}.
FT   STRAND      198    200       {ECO:0000244|PDB:3D3L}.
FT   HELIX       203    207       {ECO:0000244|PDB:3D3L}.
FT   HELIX       213    221       {ECO:0000244|PDB:3D3L}.
FT   HELIX       225    234       {ECO:0000244|PDB:3D3L}.
FT   HELIX       258    269       {ECO:0000244|PDB:3D3L}.
FT   STRAND      273    277       {ECO:0000244|PDB:3D3L}.
FT   HELIX       279    281       {ECO:0000244|PDB:3D3L}.
FT   STRAND      300    305       {ECO:0000244|PDB:3D3L}.
FT   STRAND      311    319       {ECO:0000244|PDB:3D3L}.
FT   STRAND      325    327       {ECO:0000244|PDB:3D3L}.
FT   HELIX       337    357       {ECO:0000244|PDB:3D3L}.
FT   HELIX       358    364       {ECO:0000244|PDB:3D3L}.
FT   HELIX       365    378       {ECO:0000244|PDB:3D3L}.
FT   HELIX       384    389       {ECO:0000244|PDB:3D3L}.
FT   HELIX       390    392       {ECO:0000244|PDB:3D3L}.
FT   HELIX       426    434       {ECO:0000244|PDB:3D3L}.
FT   TURN        438    441       {ECO:0000244|PDB:3D3L}.
FT   HELIX       443    449       {ECO:0000244|PDB:3D3L}.
FT   HELIX       459    482       {ECO:0000244|PDB:3D3L}.
FT   HELIX       486    491       {ECO:0000244|PDB:3D3L}.
FT   HELIX       493    503       {ECO:0000244|PDB:3D3L}.
FT   TURN        504    508       {ECO:0000244|PDB:3D3L}.
FT   HELIX       510    512       {ECO:0000244|PDB:3D3L}.
FT   HELIX       522    536       {ECO:0000244|PDB:3D3L}.
FT   HELIX       538    544       {ECO:0000244|PDB:3D3L}.
FT   HELIX       547    551       {ECO:0000244|PDB:3D3L}.
FT   HELIX       554    556       {ECO:0000244|PDB:3D3L}.
FT   STRAND      567    571       {ECO:0000244|PDB:3D3L}.
FT   HELIX       574    580       {ECO:0000244|PDB:3D3L}.
FT   HELIX       584    597       {ECO:0000244|PDB:3D3L}.
FT   HELIX       618    643       {ECO:0000244|PDB:3D3L}.
FT   HELIX       654    656       {ECO:0000244|PDB:3D3L}.
FT   STRAND      657    660       {ECO:0000244|PDB:3D3L}.
SQ   SEQUENCE   663 AA;  75694 MW;  C4D6D5B320666A77 CRC64;
     MGRYRIRVAT GAWLFSGSYN RVQLWLVGTR GEAELELQLR PARGEEEEFD HDVAEDLGLL
     QFVRLRKHHW LVDDAWFCDR ITVQGPGACA EVAFPCYRWV QGEDILSLPE GTARLPGDNA
     LDMFQKHREK ELKDRQQIYC WATWKEGLPL TIAADRKDDL PPNMRFHEEK RLDFEWTLKA
     GALEMALKRV YTLLSSWNCL EDFDQIFWGQ KSALAEKVRQ CWQDDELFSY QFLNGANPML
     LRRSTSLPSR LVLPSGMEEL QAQLEKELQN GSLFEADFIL LDGIPANVIR GEKQYLAAPL
     VMLKMEPNGK LQPMVIQIQP PNPSSPTPTL FLPSDPPLAW LLAKSWVRNS DFQLHEIQYH
     LLNTHLVAEV IAVATMRCLP GLHPIFKFLI PHIRYTMEIN TRARTQLISD GGIFDKAVST
     GGGGHVQLLR RAAAQLTYCS LCPPDDLADR GLLGLPGALY AHDALRLWEI IARYVEGIVH
     LFYQRDDIVK GDPELQAWCR EITEVGLCQA QDRGFPVSFQ SQSQLCHFLT MCVFTCTAQH
     AAINQGQLDW YAWVPNAPCT MRMPPPTTKE DVTMATVMGS LPDVRQACLQ MAISWHLSRR
     QPDMVPLGHH KEKYFSGPKP KAVLNQFRTD LEKLEKEITA RNEQLDWPYE YLKPSCIENS
     VTI
//
